Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.72 |
| ▸ | ITK | Q08881 | 1/20 | 0.54 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 3/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
| ▸ | KDM5A | P29375 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20344653 | 0.87 | HCAR2 (0.54) | HCAR2ITKRIPK1 | |
| SCHEMBL21156317 | 0.87 | HCAR2 (0.54) | HCAR2ITKRIPK1HPGDTSHR | |
| SCHEMBL12703568 | 0.84 | HCAR2 (1.00) | HCAR2HPGDTSHRTACR3 | |
| SCHEMBL23189158 | 0.82 | HCAR2 (0.72) | HCAR2RIPK1HPGDTSHRTACR3 | |
| SCHEMBL15964745 | 0.81 | HCAR2 (0.77) | HCAR2RIPK1HPGDTSHRTACR3 | |
| SCHEMBL23189249 | 0.81 | HCAR2 (0.70) | HCAR2ITKRIPK1HPGDTSHR | |
| SCHEMBL20344646 | 0.80 | HCAR2 (0.47) | HCAR2 | |
| SCHEMBL16979044 | 0.79 | HCAR2 (0.66) | HCAR2 | |
| SCHEMBL12703567 | 0.78 | HCAR2 (0.67) | HCAR2HPGDTSHRTACR3 | |
| SCHEMBL8053488 | 0.78 | HCAR2 (0.46) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3342771-B1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2019-04-18 | — | — | US | disclosed |
| EP-3342771-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Ltd (GB) | 2018-07-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190112318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | HCAR2 3504/4885ITK 567/4885RIPK1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.